Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Trading Statement

23 Mar 2009 07:00

RNS Number : 2116P
ViaLogy PLC
23 March 2009
Β 

ο»Ώ

VIALOGYΒ PLCΒ ("VIALOGY" OR "THE COMPANY")Β 

VIALOGY TECHNOLOGY DELIVERS LARGEΒ OILΒ FIND

Β 

LONDON,Β March 23rd, 2009Β - ViaLogyΒ PLCΒ (LSE: VIY).Β ViaLogy announces today that its QuantumRDβ„’ oil exploration technology and service has been credited with locating a major new oil deposit on the Galba Prospect in South Central Texas. The success marks the operational and commercial validation of ViaLogy's software-based seismic interpretation service for oil and gas reservoir discovery and characterization. The technology accurately predicted the size, location and porosity of three reservoirs.Β 

The successful drilling effort and oil strike based on the ViaLogy analysis located reservoirs at increasing depths estimated to contain a total of over 2 million barrels of recoverable reserves.Β ViaLogy's contract with Atascosa Exploration LLC, ofΒ San Antonio,Β Texas, for the Galba Prospect foresees multiple wells on the lease, now determined to be 4 or 5, targeted at the three reservoirs and positioned by ViaLogy. The first well, just completed, has located a reservoir with an estimated oil deposit which will produce 153,000 barrels of crude oil (i.e. 35% primary recovery based on an overall actual volume of 460,000 barrels). Atascosa plans extractions of 50% of the recoverable reserves in first three years. Under its contract with Atascosa, ViaLogy will receive a 5% Back-In-After-Payout (BIAPO) working interest. This means that after costs ViaLogy will receive over $300KΒ duringΒ the life of this first well (assuming oil price at $40 per barrel). Galba Prospect production will begin immediately. For the entire field, ViaLogy could receive 5% of the 2 million barrels over the lifetime of the field's wells which, assuming an average $40 oil price, would produce around $4 million.

ViaLogy's role in the Galba Prospect project included the design and acquisition of new, high-resolution 3D seismic survey data, integrated geoseismic and geological assessment, and positioning of the drill site. ViaLogy collaborated closely with Atascosa's geology and production team. Oil was found at the depth and with the porosity ViaLogy predicted in the Upper Wilcox formation, and all other parameters conformed toΒ ViaLogy's analysis and its determination of coordinates for the drilling site.

ViaLogy believes that its geoseismic interpretation technology will address a problem faced by the oil industry worldwide - to avoid drilling dry holes. InΒ Texas, only four out of 10 exploratory wells, including those drilled with the aid of seismic, find oil or gas in economically producible quantities. Abortive attempts are costly. According to US Dept. of Energy (DOE) Energy Information Administration (EIA) statistics, the 2006 average cost for drilling an on-shore dry hole in theΒ USΒ was over $450,000. The success of the Galba Project reinforces QuantumRD's value proposition for locating oil reservoirs while lowering the probability of dry holes, and thus reducing the overall cost of exploration.Β 

Working with Atascosa, ViaLogy plans to market the QuantumRD technology and service initially to US independent exploration companies. QuantumRD is a computational technology based on ViaLogy's patented QuantumΒ Resonance Interferometry (QRIβ„’), an active signal processing technique capableΒ of significantly increasing the signal to noise ratio of seismic data and improving its value.

Commenting on the Galba Prospect find, Atascosa's Chief Executive, John Mullins, said: "We're very pleased with the success of this well. We have increased our lease positions at the prospect, and are planning to further grow our collaboration with ViaLogy on Galba and other prospects. Our geology team has been working with the ViaLogy scientists for some months now, and we're highly impressed with the technology behind QuantumRD. The accuracy of the results is remarkable and the payoff is reducing the risk of dry holes."

He added, "The quality of the information relating to the size and content of the reservoirs enables us to position the wells to extract the maximum amount of hydrocarbons."

ViaLogy's CEO, Robert W. Dean, commented: "Our success inΒ TexasΒ validates QuantumRD, and is a key step in building a services business in the oil and gas industry. We have a potentially global product, but initially we intend to focus our sales efforts for our oil detection technology and services on US-based independent exploration companies. Going forward, we expect it will be attractive to established seismic data companies, oil field services companies, and the oil majors."

For further information please contact:

ViaLogy

Robert W Dean, President & CEO -Β USΒ +1 626-296-6337 (mobile: +1 703-589-3807) Terry Bond, Chairman - UK & Europe +44 (0) 1235-834734 (mobile: 07860 842756)

Atascosa Exploration LLCΒ Β  John D. Mullins, CEO (+1 210-402-3656)Β 

Nominated Advisor (SeymourΒ Pierce)Β Β  Mark Percy +44 (0) 20-7107-8000Β 

Brokers to ViaLogyΒ PLCΒ 

Sebastian Wykeham, St. Helen's Capital - +44 (0) 7628 5582Β 

About ViaLogy: Network Centric Signal ProcessingΒ Β  ViaLogy is a leading innovator of network-centric, real-time signal processing platforms for sensor applications. ViaLogy is currently deploying and designing computational systems, powered by its patented technologies, for applications in life sciences, public safety and security, surveillance, defense and geoseismology. ViaLogy focuses on market driven problems where automation, timeliness, quality and reliability of information processing are essential. ViaLogy's core competency incorporates rapidly and accurately detecting weak signals buried in high noiseΒ background and clutter. This technology can be employed to solve problems involving sensor integration and information overload challenges involving video, telephony and control sensors, as well as for enhancement of numerous signal processing applications. For more information, visit our website atΒ www.ViaLogy.com.Β 

Except for statements of historical fact, the information presented herein constitutes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied.


This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
TSTPUURWWUPBGGU
Date   Source Headline
1st Apr 201912:12 pmRNSHolding(s) in Company
25th Mar 20197:00 amRNSYourgene raises IONA® test awareness in Egypt
26th Feb 20193:21 pmRNSHolding(s) in Company
22nd Feb 201910:00 amEQSHardman & Co Research: Yourgene Health (YGEN): EBITDA-positive in fiscal 2020
22nd Feb 20198:05 amRNSHolding(s) in Company
19th Feb 20192:21 pmRNSHolding(s) in Company
19th Feb 20197:15 amEQSHardman & Co Research: Yourgene Health (YGEN): Transformed and de-risked
18th Feb 201910:59 amRNSIssue of Equity
18th Feb 20197:00 amRNSMajor Capital & Commercial Restructuring
8th Jan 20197:00 amRNSYourgene launches Sage 32 plex
3rd Dec 20187:00 amRNSHalf-year Results
7th Nov 20187:00 amRNSChange of Name to Yourgene Health plc
5th Nov 201811:24 amRNSShare Transfer
2nd Nov 20187:00 amRNSDirectorate Change
25th Oct 20183:30 pmRNSResult of AGM
25th Oct 20187:00 amRNSHolding(s) in Company
25th Oct 20187:00 amRNSAGM Statement
22nd Oct 20187:00 amRNSFurther re: Fundraise
12th Oct 20181:15 pmRNSAvailability of Research Commentary
12th Oct 20187:00 amRNSTrading Update and Notice of Results
5th Oct 20187:00 amRNSDirector's dealing and share option issue
4th Oct 20187:00 amRNS$1 million collaboration agreement
3rd Oct 20187:00 amRNSDirectorate change
2nd Oct 20187:00 amRNSNotice of AGM
1st Oct 201812:20 pmRNSResult of Fundraise
28th Sep 20185:41 pmRNSProposed fundraise to raise approximately £2.5m
28th Sep 20185:40 pmRNSFull year results and half-year trading update
25th Sep 201811:31 amRNSHolding(s) in Company
21st Sep 20184:10 pmRNSHolding(s) in Company
21st Sep 20187:00 amRNSHolding(s) in Company
20th Sep 20189:30 amRNSSenior Appointment & Anticipated Director Change
19th Sep 201811:05 amRNSSecond Price Monitoring Extn
19th Sep 201811:00 amRNSPrice Monitoring Extension
19th Sep 20187:00 amRNSLegal Settlement & Licence Agreement with Illumina
11th Sep 20187:00 amRNSHolding(s) in Company
7th Aug 201810:57 amRNSHolding(s) in Company
12th Jul 20187:00 amRNSShare option awards
4th Jul 20187:00 amRNSBoard Changes
26th Jun 20181:31 pmRNSCollaboration with Abnova
13th Jun 20187:00 amRNSOutstanding NIPS Solution Provider Award Win
11th Jun 20187:00 amRNSDNA sequencing technology development agreement
7th Jun 20183:44 pmRNSHolding(s) in Company
5th Jun 20187:00 amRNSPremaitha signs partnership agreement in India
4th Jun 201811:05 amRNSHolding(s) in Company
24th May 20187:00 amRNSHolding(s) in Company
18th May 20184:38 pmRNSHolding(s) in Company
18th May 201812:06 pmRNSHolding(s) in Company
18th May 201812:05 pmRNSHolding(s) in Company
18th May 20189:40 amRNSHoldings in Company
15th May 20187:00 amRNSPremaitha expands footprint with new laboratories

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.